-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1175

Benzinga·11/02/2026 12:44:49
Listen to the news
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $922 to $1175.